|
|
-
Gilead Sciences Says EMA Validates Co's Marketing Application For Sofosbuvir For Treatment Of Hepatitis C
5/21/2013
|
|
|
|
|
-
Gilead Sciences Announces Response Data From Phase 2 Study Of Idelalisib
5/15/2013
|
|
|
-
Barclays Capital Is Lowering Gilead Sciences Inc. (GILD) FY14 Estimate To 3.17 From 3.21
5/3/2013
|
-
Barclays Capital Is Cutting Gilead Sciences Inc. (GILD) FY13 Estimate To 1.95 From 1.98
5/3/2013
|
|
|
|
|